PISCES
01 Dec 2020
Trial Summary
Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.
Acronym:
KEYNOTE 695
ACTRN/NCT /ethics:
NCT03132675
Scientific title:
A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)
Sponsor / Cooperative group:
OncoSec Medical Incorporated
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Melanoma |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2017-10-03 |
| Anticipated End Date | 2023-07-31 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Recruiting |